24 completed, 6 terminated, 4 unknown, 3 recruiting. 23 Phase 3, 19 Phase 2, 1 Early Phase 1, 1 Phase 1.
Follow AB Science: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Masitinib in Patients With Mild Alzheimer's Disease Placebo, Masitinib (4.5), Standard of care - Alzheimer Disease | Phase 3 | Not yet recruiting | AB Science | 600 | 2026-06-01 | 2025-10-03 |
| Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients Masitinib 4.5 mg/kg/day, Placebo, Riluzole (100 mg) - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Not yet recruiting | AB Science | 412 | 2026-01-01 | 2025-10-03 |
| Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study. Multiple Sclerosis, NMO Spectrum Disorder | Recruiting | icometrix | 7000 | 2024-03-01 | 2025-12-12 | |
| Masitinib for the Treatment of Severe Mast Cell Activation Syndrome Masitinib 4.5 mg/kg/day, Placebo, Best supportive care - Mast Cell Activation Syndrome | Phase 2 | Unknown | AB Science | 72 | 2022-07-01 | 2023-02-06 |
| Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis Placebo, Masitinib (4.5) - Progressive Multiple Sclerosis | Phase 3 | Suspended | AB Science | 800 | 2022-06-28 | 2026-05-06 |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia AB8939, Venetoclax - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | AB Science | 78 | 2022-06-01 | 2025-10-02 |
| Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Masitinib Mesylate, Placebo - Covid19, SARS-CoV2 Infection | Phase 2 | Unknown | AB Science | 78 | 2021-11-23 | 2023-02-06 |
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Masitinib (6.0), Riluzole, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Recruiting | AB Science | 495 | 2021-02-02 | 2025-09-12 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
| Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 Masitinib, Isoquercetin, Best Supportive Care - SARS-CoV 2, COVID-19 | Phase 2 | Unknown | AB Science | 200 | 2020-06-01 | 2023-02-06 |
| Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects 14C-AB1010 - Healthy Volunteers | Early Phase 1 | Completed | AB Science | 4 | 2017-07-31 | 2022-01-21 |
| Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels Masitinib, Placebo - Asthma | Phase 3 | Completed | AB Science | 347 | 2016-12-01 | 2020-12-08 |
| Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence Masitinib, Placebo - Gastro-Intestinal Stromal Tumour | Phase 3 | Terminated | AB Science | 7 | 2015-07-01 | 2018-12-14 |
| Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer Masitinib - Colorectal Cancer Metastatic | Phase 2 / Phase 3 | Completed | AB Science | 219 | 2015-07-01 | 2020-12-08 |
| Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer Masitinib, Docetaxel, Prednisone - Metastatic Castrate Resistant Prostate Cancer | Phase 3 | Completed | AB Science | 714 | 2014-09-01 | 2023-09-29 |
| Masitinib Plus Gemcitabine in Pancreatic Cancer Masitinib, Gemcitabine, Placebo - Locally Advanced or Metastatic Pancreatic Cancer | Phase 3 | Completed | AB Science | 377 | 2014-07-01 | 2020-12-08 |
| Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients Masitinib, Gemcitabine, Placebo - Ovarian Cancer | Phase 2 / Phase 3 | Completed | AB Science | 248 | 2014-04-01 | 2020-12-08 |
| Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer Masitinib (AB1010), FOLFIRI - Metastatic Colorectal Cancer | Phase 3 | Terminated | AB Science | 123 | 2014-01-01 | 2019-02-11 |
| Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Masitinib (4.5), Riluzole, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Completed | AB Science | 394 | 2013-04-01 | 2023-09-29 |
| Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib Masitinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 3 | Completed | AB Science | 258 | 2012-04-01 | 2020-12-08 |
Showing 20 of 40. Sign in to see all of them.
Mastocytosis (4) · Alzheimer Disease (3) · Amyotrophic Lateral Sclerosis (3) · Arthritis, Rheumatoid (3) · Asthma (3) · Multiple Sclerosis (3) · Multiple Sclerosis, Chronic Progressive (3) · Blushing (2) · COVID-19 (2) · Gastrointestinal Stromal Tumors (2) · Mastocytosis, Systemic (2) · Multiple Myeloma (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Piebaldism (2)
masitinib (37) · Gemcitabine (3) · Riluzole (3) · Standard of Care (2) · Sunitinib (2) · Bortezomib (1) · Dacarbazine (1) · Dexamethasone (1) · Docetaxel (1) · IFL protocol (1) · Imatinib Mesylate (1) · Methotrexate (1) · Prednisone (1) · isoquercitrin (1) · venetoclax (1)
France (24) · Spain (11) · Russia (9) · United States (9) · Greece (7) · Ukraine (7) · Czechia (6) · Germany (5) · Italy (5) · Poland (5) · United Kingdom (5) · Romania (4) · Bulgaria (3) · India (3) · Belgium (2)
Olivier Lortholary, MD, PhD (3) · Lavinia Davidescu, MD, PhD (2) · Albert Ludolph, MD, PhD (1) · Antoine Adenis, MD (1) · Axel Le Cesne, M.D., Ph.D (1) · Axel Le Cesne, MD (1) · Bertrand Arnulf, MD (1) · Bruno Dubois, MD, PhD (1) · Cristina Bulai Livideanu, MD, MSc (1) · Dominique Spaeth, MD (1) · Friedemann Paul, PhD, MD (1) · Jacques Tebib, MD (1)
PMID 36048877, PMID 19549290, PMID 19614621, PMID 20211560, PMID 21108325, PMID 21504563, PMID 22691628, PMID 25122671, PMID 25858497, PMID 28069279, PMID 34457038, PMID 35190477, PMID 36849969, PMID 37117213
2016 (1), 2017 (1)